nach oben

Erschienen in:

01.07.2004 | Original Article

NY-ESO-1 expression and its serum immunoreactivity in esophageal cancer

verfasst von: Argun Akcakanat, Tatsuo Kanda, Yu Koyama, Michitoshi Watanabe, Eiji Kimura, Yutaka Yoshida, Shintarou Komukai, Satoru Nakagawa, Shoji Odani, Hiroshi Fujii, Katsuyoshi Hatakeyama

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 1/2004

Einloggen, um Zugang zu erhalten

Abstract

Purpose

NY-ESO-1, a member of the cancer/testis antigen (CTA) family, elicits humoral and cellular immune responses in patients with advanced cancer. Unresectable or metastatic esophageal carcinoma patients do not benefit from the present multimodality treatment regimens in terms of survival. The objectives of this study were to analyze the antibody response to NY-ESO-1 antigen in patients with esophageal cancer and to determine the potential of NY-ESO-1 for use in tumor-specific immunotherapy.

Methods

Serum from 69 patients with esophageal cancer was investigated for antibody production against NY-ESO-1 by Western blot analysis. Also analyzed by immunohistochemistry were 56 tissue samples from these patients for NY-ESO-1 protein expression.

Results

NY-ESO-1 protein expression was found in 18 of 56 (32%) esophageal carcinomas. Serum immunoreactivity specific for NY-ESO-1 was found in 9 patients (13%) of whom 8 were in the advanced stage (stages III and IV). There was no relationship between clinicopathologic features and serum immunoreactivity for NY-ESO-1. NY-ESO-1 protein expression was detected in three of five antibody-positive patients whose tissue was available for analysis. Survival analysis showed no significant difference between antibody-positive and antibody-negative patient groups.

Conclusions

A humoral immune response to NY-ESO-1 antigen was established in patients with advanced esophageal cancer. NY-ESO-1 is a good candidate for vaccine-based immunotherapy for advanced esophageal carcinoma.

American Joint Committee on Cancer (2002) AJCC cancer staging manual (6th edn). Springer-Verlag, New York Berlin Heidelberg

Ando N, Iizuka T, Ide H, Ishida K, Shinoda M, Nishimaki T, Takiyama W, Watanabe H, Isono K, Kinjo Y, Fukuda H (1999) A randomized trial of surgery alone vs surgery plus chemotherapy with cisplatin and 5-fluorouracil for localized squamous carcinoma of the thoracic esophagus: the Japan Clinical Oncology Group study. Proc Am Soc Clin Oncol 18:269a

Chen Y-T, Scanlan MJ, Sahin U, Tureci O, Gure AO, Tsang S, Williamson B, Stockert E, Pfreundschuh M, Old LJ (1997) A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A 94:1914–1918CrossRefPubMed

De Plaen E, Arden K, Traversari C, Gaforio JJ, Szikora J-P, De Smet C, Brasseur F, van der Bruggen P, Lethe B, Lurquin C, Brasseur R, Chomez P, De Backer O, Cavenee W, Boon T (1994) Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics 40:360–369

Haffejee AA, Angorn IB (1979) Nutritional status and the nonspecific cellular and humoral immune response in esophageal carcinoma. Ann Surg 189:475–479PubMed

Heroor A, Fujita H, Sueyoshi S, Tanaka T, Toh U, Mine T, Sasahara H, Sudo T, Matono S, Yamana H, Shirouzu K (2003) Adjuvant chemotherapy after radical resection of squamous cell carcinoma in the thoracic esophagus: who benefits? A retrospective study. Dig Surg 20:229–235CrossRefPubMed

Hofstetter W, Swister SG, Correa AM, Hess K, Putnam JB Jr, Ajani JA, Dolormente M, Francisco R, Komaki RR, Lara A, Martin F, Rice DC, Sarabia AJ, Smythe WR, Vaporciyan AA, Walsh GL, Roth JA (2002) Treatment outcomes of resected esophageal cancer. Ann Surg 3:376–385CrossRef

Jager E, Chen Y-T, Drijfhout JW, Karbach J, Ringhoffer M, Jager D, Arand M, Wada H, Noguchi Y, Stockert E, Old LJ, Knuth A (1998) Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 187:265–270PubMed

Jager E, Stockert E, Zidianakis Z, Chen Y-T, Karbach J, Jager D, Arand M, Ritter G, Old LJ, Knuth A (1999) Humoral immune responses of cancer patients against “cancer-testis” antigen NY-ESO-1: correlation with clinical events. Int J Cancer 84:506–510CrossRefPubMed

10.

Japanese Society for Esophageal Diseases (2002) Comprehensive registry of esophageal cancer in Japan (1998, 1999) & long-term results of esophagectomy in Japan (1988–1997) (3rd edn). Japanese Society for Esophageal Diseases, Chiba, Japan

11.

Jungbluth AA, Antonescu CR, Busam KJ, Iversen K, Kolb D, Coplan K, Chen YT, Stockert E, Ladanyi M, Old LJ (2001) Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE A-1 or CT7. Int J Cancer 94:252–256CrossRefPubMed

12.

Jungbluth AA, Chen Y-T, Stockert E, Busam KJ, Kolb D, Iversen K, Coplan K, Williamson B, Altorki N, Old LJ (2001) Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer 92:856–860CrossRefPubMed

13.

Lee L, Wang R-F, Wang X, Mixon A, Johnson BE, Rosenberg SA, Schrump DS (1996) NY-ESO-1 may be a potential target for lung cancer immunotherapy. Cancer J Sci Am 5:20–25

14.

Lee S-Y, Obata Y, Yoshida M, Stockert E, Williamson B, Jungbluth AA, Chen YT, Old LJ, Scanlan MJ (2003) Immunomic analysis of human sarcoma. Proc Natl Acad Sci U S A 100:2651–2656CrossRefPubMed

15.

Maio M, Coral S, Sigalotti L, Elisei R, Romei C, Rossi G, Cortini E, Colizzi F, Fenzi G, Altomonte M, Pinchera A, Vitale M (2003) Analysis of cancer/testis antigens in sporadic medullary thyroid carcinoma: expression and humoral response to NY-ESO-1. J Clin Endocrinol Metab 88:748–754CrossRefPubMed

16.

Mashino K, Sadanaga N, Tanaka F, Yamaguchi H, Nagashima H, Inoue H, Sugimachi K, Mori M (2001) Expression of multiple cancer-testis antigen genes in gastrointestinal and breast carcinomas. Br J Cancer 85:713–720PubMed

17.

Mukaida H, Hirai T, Yamashita Y (1998) Clinical evaluation of adjuvant chemotherapy with CDDP, 5-FU, and VP-16 for advanced esophageal carcinoma. Jpn J Thorac Cardiovasc Surg 46:11–17PubMed

18.

Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4:328–332PubMed

19.

Okuno K, Tanaka A, Yoshikawa H, Shigeoka H, Jinnai H, Lee YS, Hirai N, Matsumura E, Kawai I, Yasutomi M (1998) A new preoperative immunochemotherapy for the treatment of locally advanced esophageal cancer. Hepatogastroenterology 45:950–953PubMed

20.

Peng LP, Liu HY, Rau YL, Sun LX, Yu L, Yang ZH (2002) Expression of NY-ESO-1 gene in human esophageal carcinoma and its cloning. Ai Zheng 21:468–472

21.

Renkvist N, Castelli C, Robbins PF, Parmiani G (2001) A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 50:3–15PubMed

22.

Saito T, Kuwahara A, Kinoshita T, Shigemitsu Y, Shimoda K, Miyahara M, Kobayashi M (1992) Increases in immunoglobulin and complement in patients with esophageal or gastric cancer. Surg Today 22:537–542PubMed

23.

Stockert E, Jager E, Chen Y-T, Scanlan MJ, Gout I, Karbach J, Arand M, Knuth A, Old LJ (1998) A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 187:1349–1354PubMed

24.

Toh U, Yamana H, Sueyoshi S, Tanaka T, Niiya F, Katagiri K, Fujita H, Shirozou K, Itoh K (2000) Locoregional cellular immunotherapy for patients with advanced esophageal cancer. Clin Cancer Res 6:4663–4673PubMed

25.

Toh U, Sudo T, Kido K, Matono S, Sasahara H, Mine T, Tanaka T, Sueyoshi S, Fujita H, Shirouzu K, Yamana H (2002) Locoregional adoptive immunotherapy resulted in regression in distant metastases of a recurrent esophageal cancer. Int J Clin Oncol 7:372–375PubMed

26.

Tsutsui S, Sonoda K, Sumiyoshi K, Kitamura K, Toh Y, Kitamura M, Kuwano H, Sugimachi K, Okamura S (1996) Prognostic significance of immunological parameters in patients with esophageal cancer. Hepatogastroenterology 43:501–509PubMed

27.

Verra N, Jansen R, Groenewegen G, Mallo H, Kersten MJ, Bex A, Vyth-Dreese FA, Sein J, van de Kasteele W, Nooijen WJ, de Waal M, Horenblas S, de Gast GC (2003) Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinoma. Br J Cancer 88:1346–1351CrossRefPubMed

28.

Zambon A, Madruzzato S, Parenti A, Macino B, Dalerba P, Ruol A, Merigliano S, Zaninotto G, Zanovello P (2001) MAGE, BAGE, and GAGE gene expression in patients with esophageal squamous cell carcinoma and adenocarcinoma of the gastric cardia. Cancer 91:1182–1188CrossRef

Titel: NY-ESO-1 expression and its serum immunoreactivity in esophageal cancer
verfasst von: Argun Akcakanat
Tatsuo Kanda
Yu Koyama
Michitoshi Watanabe
Eiji Kimura
Yutaka Yoshida
Shintarou Komukai
Satoru Nakagawa
Shoji Odani
Hiroshi Fujii
Katsuyoshi Hatakeyama
Publikationsdatum: 01.07.2004
Verlag: Springer-Verlag
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 1/2004
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-004-0768-3

Neu im Fachgebiet Onkologie

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gut molekulare Response, aber seltener ernste Nebenwirkungen.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Brustkrebs-Prävention wird neu gedacht

04.06.2024 ASCO 2024 Kongressbericht

Zurzeit untersuchen Forschende verschiedene neue Ansätze zur Prävention von Brustkrebs bei Personen mit hohem Risiko. Darunter Denosumab, die prophylaktische Bestrahlung der Brust – und Impfungen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

NY-ESO-1 expression and its serum immunoreactivity in esophageal cancer